Lumenis shareholders approved the company’s $510 million sale to Hong Kong-based XIO group, according to an SEC filing posted yesterday.
Lumenis makes energy-based medical devices for surgical, ophthalmological and aesthetic applications.
Yokneam, Israel-based Lumenis will become a wholly-owned subsidiary of an Israel-based company that is indirectly wholly-owned by XIO, according to the SEC filing.
In June, Lumenis agreed to a $510 million acquisition bid from the Hong Kong-based “alternative investments” shop.
Lumenis, which raised $75 million in an initial public offering last year, was said in February to be in talks about a buyout by Chinese conglomerate Fosun for nearly $500 million. The company said XIO Group put up a $14-per-share cash offer.
In November 2013, Lumenis won clearance in the U.S. and Japan for its Array LaserLink pattern scanning device for multi-spot retinal laser treatment.
Earlier in 2013, the FDA slapped the company with a Class I recall of its VersaCut morcellator.
